Three Q3 filers raise full-year guidance as growth broadens beyond one sector

The guidance pattern

The point of this filing batch is the guidance, not just the quarter. Palantir, Vertex Pharmaceuticals and Hinge Health each raised full-year 2026 revenue guidance alongside third-quarter results, the companies say in their filings. Palantir lifted its range to $8.530 billion to $8.534 billion and set fourth-quarter revenue guidance of $2.649 billion to $2.653 billion. Vertex lifted its range to $13.15 billion to $13.25 billion. Hinge Health lifted its range to $879 million to $881 million, with fourth-quarter revenue guidance of $249 million to $251 million. m:…8471 m:…2746 m:…9331

Palantir reported the fastest growth in the group. Its filing puts third-quarter revenue at $2.313 billion, up 96% year over year, with GAAP net income of $1.128 billion. United States commercial revenue grew 148% to $984 million, and the company says it closed 212 deals of at least $1 million in the quarter. Remaining deal value in United States commercial reached $6.517 billion, up 79% year over year. The company also reported $10.4 billion in cash, cash equivalents and Treasury securities at quarter end. m:…8471

Vertex grew more slowly but from a much larger base. Its filing reports third-quarter revenue of $3.44 billion, up 12% year over year, with GAAP net income of $654 million, down from $1.1 billion a year earlier. The company says it completed the acquisition of Crinetics Pharmaceuticals on September 1, 2026, and that combined expenses included about $500 million of compensation and transaction-related costs tied to that deal. Cash, cash equivalents and marketable securities stood at $9.8 billion at September 30, 2026. m:…2746

Health and streaming broaden the picture

Hinge Health reported third-quarter revenue of $235 million, up 52% year over year, with free cash flow of $112.7 million, the company says in its filing. Its client count reached 3,270 at September 30, 2026, up 28% year over year. The company says its gastrointestinal care client base grew roughly 40% since the August 2026 announcement of the Cylinder Health acquisition. It also announced that president Jim Pursley will step down effective January 1, 2027, join the board effective January 4, 2027, and hand commercial leadership to Aaryn Pure. m:…9331

Roku is the exception that keeps the pattern honest. Its filing reports third-quarter net revenue of $1.5 billion, up 24% year over year, with platform revenue of $1.3 billion, up 23%. Advertising revenue grew 23% to $727 million and subscription revenue grew 23% to $581 million. Net income was $183 million and adjusted EBITDA was $249 million. The filing summary contains no guidance raise for Roku, so the quarter reads as broad operating growth rather than a lifted outlook. m:…5233

Roku also reported trailing twelve-month free cash flow of $796 million and streaming hours of 39.9 billion, up 9% year over year. More than 80% of in-stream video ad impressions were delivered programmatically in the quarter, the company says. It completed the United States rollout of its new Home Screen in July 2026 and is now rolling it out internationally. The detail matters because it ties the revenue growth to distribution and ad delivery, not to a single content event. m:…5233

What the raises do and do not show

Guidance is a company forecast, not a result, and the three raises rest on different drivers. Palantir raised its adjusted free cash flow guidance to $4.8 billion to $5.0 billion alongside the revenue raise, the company says. Vertex points to product milestones ahead, including expected revenue of $40 million to $50 million from PALSONIFY for the rest of 2026, reimbursement for ALYFTREK in seven additional countries during the quarter, CASGEVY revenue of $99 million, and a November 30, 2026 regulatory decision date for povetacicept in IgAN. A reader should treat those as company-stated expectations to be tested by delivery, not as confirmed outcomes. m:…8471 m:…2746

The near-term test is straightforward: fourth-quarter revenue against the new ranges, plus the items each company flagged for itself. For Hinge Health, that includes the January leadership transition and whether client growth holds; the company reported GAAP diluted net income per share of $0.66 for the quarter. For Roku, it includes whether the international Home Screen rollout sustains the advertising and subscription growth shown in the third quarter. Guidance raises across unrelated sectors are a useful signal of management confidence, but they are only as good as the next quarter of filings. m:…9331 m:…5233